Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin

International Journal of Laboratory Hematology

Volumn 36, Issue 3, 2014, Pages 341-351

  Graf, L ^a   Moffat, K A ^a,b   Carlino, S A ^b   Chan, A K C ^a   Iorio, A ^a   Giulivi, A ^c   Hayward, C P M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Diagnostic testing; Von Willebrand disease; Von Willebrand factor; Von Willebrand factor activity

Indexed keywords

BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; IMMUNOGLOBULIN G; PARAPROTEIN; RISTOCETIN; VON WILLEBRAND FACTOR;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOMATION; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS EQUIPMENT; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; THROMBOCYTHEMIA; BLOOD; BLOOD EXAMINATION; DIAGNOSTIC USE; GENETICS; LABORATORY AUTOMATION; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROCEDURES; REPRODUCIBILITY; STANDARDS; VERY ELDERLY; VON WILLEBRAND DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOMATION, LABORATORY; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOLOGIC TESTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; RISTOCETIN; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84898678042     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12218     Document Type: Article

References (36)

1. Cox Gill J. Diagnosis and treatment of von Willebrand disease. Hematol Oncol Clin North Am 2004;18:1277-99.
2. Schneppenheim R. The pathophysiology of von Willebrand disease: therapeutic implications. Thromb Res 2011;128(Suppl. 1):S3-7.
3. James PD, Lillicrap D. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. Am J Hematol 2012;87(Suppl. 1):S4-11.
4. Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol 2009;121:71-84.
5. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4:2103-14.
6. Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 2006;32:492-8.
7. Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia 2011;17:252-6.
8. Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, Peyvandi F. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia 2013;19:338-42.
9. Bowyer AE, Shepherd F, Kitchen S, Makris M. A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease. Thromb Res 2011;127:341-4.
10. Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014;20:147-53.
11. Chandler WL, Peerschke EI, Castellone DD, Meijer P. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Path 2011;135:862-9.
12. Hayes TE, Brandt JT, Chandler WL, Eby CS, Kottke-Marchant K, Krishnan J, Lefkowitz JB, Olson JD, Rund CR, Van Cott EM, Cunningham MT. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost 2006;32:499-504.
13. Strandberg K, Lethagen S, Andersson K, Carlson M, Hillarp A. Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity. Clin Appl Thromb Hemost 2006;12:61-7.
14. Caron C, Hilbert L, Vanhoorelbeke K, Deckmyn H, Goudemand J, Mazurier C. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease. Br J Haematol 2006;133:655-63.
15. Zhao Y, Gu Y, Ji S, Yang J, Yu Z, Ruan C. Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease. Eur J Haematol 2012;88:439-45.
16. Berntorp E, Fuchs B, Makris M, Montgomery R, Flood V, O'Donnell JS, Federici AB, Lillicrap D, James P, Budde U, Morfini M, Petrini P, Austin S, Kannicht C, Jiménez-Yuste V, Lee C. Third Aland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. Haemophilia 2013;19(Suppl. 3):1-18.
17. Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood 2013;121:3742-4.
18. Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009;7:1832-9.
19. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007;33:727-44.
20. Bolton-Maggs PH, Favaloro EJ, Hillarp A, Jennings I, Kohler HP. Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders. Haemophilia 2012;18(Suppl. 4):66-72.
21. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013;122:3735-40.
22. Castaman G, Goodeve A, Eikenboom J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica 2013;98:667-74.
23. Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. Semin Thromb Hemost 2012;38:742-52.
24. Hayward CP, Moffat KA, Pai M, Liu Y, Seecharan J, McKay H, Webert KE, Cook RJ, Heddle NM. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thromb Haemost 2008;100:134-45.
25. Taylor JM, Cumberland WG, Meng X, Giorgi JV. Normal range estimation for repeated immunologic measures. Clin Diagn Lab Immunol 1996;3:139-42.
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
27. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P; UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006;96:630-41.
28. Corrales I, Ramirez L, Altisent C, Parra R, Vidal F. Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost 2009;101:570-6.
29. Casana P, Martinez F, Espinos C, Haya S, Lorenzo JI, Aznar JA. Search for mutations in a segment of the exon 28 of the human von Willebrand factor gene: new mutations, R1315C and R1341W, associated with type 2M and 2B variants. Am J Hematol 1998;59:57-63.
30. Allen S, Abuzenadah AM, Hinks J, Blagg JL, Gursel T, Ingerslev J, Goodeve AC, Peake IR, Daly ME. A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood 2000;96:560-8.
31. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006;108:3344-51.
32. Chegeni R, Vickars L, Favaloro EJ, Lillicrap D, Othman M. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease. Thromb Res 2011;127:161-6.
33. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of AB0 blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-5.
34. ISTH-SSC VWF Online Database [Internet]. The University of Sheffield. available from http://www.ragtimedesign.com/vwf/mutation/ [cited 2014, Jan 15].
35. Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 2011;22:553-64.
36. Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost 2012;10:1043-54.